Tara L Lin
Overview
Explore the profile of Tara L Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, et al.
Blood Adv
. 2025 Feb;
PMID: 39928953
We conducted a multi-center, open-label, randomized phase II study to assess the efficacy of Nivolumab as maintenance therapy for patients with AML in first complete remission (CR) or CR with...
2.
Uy G, Pullarkat V, Baratam P, Stuart R, Walter R, Winer E, et al.
Blood Adv
. 2024 Oct;
8(24):6248-6256.
PMID: 39418644
Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 inhibitor. This phase 1b study evaluated lower-intensity CPX-351 combined...
3.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
4.
Litzow M, Sun Z, Mattison R, Paietta E, Roberts K, Zhang Y, et al.
N Engl J Med
. 2024 Jul;
391(4):320-333.
PMID: 39047240
Background: Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab,...
5.
Kasner M, Fritsche A, Leong M, Cameron K, Lee C, Lin T, et al.
JCO Oncol Pract
. 2024 Jul;
20(12):1612-1619.
PMID: 38950320
Purpose: Cancer center clinical trial offices (CCTOs) support trial development, activation, conduct, regulatory adherence, data integrity, and compliance. In 2018, the Association of American Cancer Institutes (AACI) Clinical Research Innovation...
6.
Ratnayake I, Do A, Gajewski D, Pepper S, Ige O, Streeter N, et al.
Res Sq
. 2024 May;
PMID: 38699379
Background: Drug development in cancer medicine depends on high-quality clinical trials, but these require large investments of time to design, operationalize, and complete; for oncology drugs, this can take 8-10...
7.
Shi X, Mudaranthakam D, Wick J, Streeter D, Thompson J, Streeter N, et al.
Contemp Clin Trials Commun
. 2024 Feb;
38:101281.
PMID: 38419809
Introduction: Slow patient accrual in cancer clinical trials is always a concern. In 2021, the University of Kansas Comprehensive Cancer Center (KUCC), an NCI-designated comprehensive cancer center, implemented the Curated...
8.
Male H, Lin T
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):186-191.
PMID: 38066860
Treatment options for acute myeloid leukemia (AML) have expanded over the last 5 years. New regimens are increasing the options for patients who previously may not have been offered any...
9.
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, et al.
Leukemia
. 2023 Nov;
38(1):58-66.
PMID: 37935977
Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a...
10.
Sastow D, Tatarian J, Salib C, Lin T, Tremblay D
Leuk Lymphoma
. 2023 Nov;
65(1):141.
PMID: 37921261
No abstract available.